Recruiting

Alzheimer's

Sponsor:

Bio Conscious Technologies Inc.

Code:

NCT04614376

Conditions

Mild Cognitive Impairment

Alzheimer Disease

Eligibility Criteria

Sex: All

Age: 50+

Healthy Volunteers: Accepted

Study Details

Brief summary:

The Alzheimer's and Blood Glucose Levels Study is researching the differences in blood glucose levels between people with and without Mild Cognitive Impairment or Alzheimer's disease with the aim of early detection of Alzheimer's Disease.

Conditions

Mild Cognitive Impairment

Alzheimer Disease

Study ID

NCT04614376

Start date

Nov, 2020

Status verified date

Nov, 2020

Completion date

Mar, 2022

Anticipated

Primary completion date

Aug, 2021

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 50+

Healthy Volunteers: Accepted

Inclusion Criteria:

  • For the case group: have been diagnosed with MCI or AD within the past 5 years.
  • For the control group: have not been diagnosed with MCI or AD or another major dementia disease
  • Currently using a continuous glucose monitor (CGM).
  • Willing and able to provide informed consent, and to have their data collected through the Endobits Companion app. If the participant themself is unable to provide informed consent, it will be sought from their primary caregiver.

Exclusion Criteria:

  • Patients younger than 50 years of age.
  • Patients with a BMI lower than 18 or higher than 35.
  • Patients with a major psychiatric illness (e.g., major depressive disorder, schizophrenia, bipolar disorder)
  • Patients diagnosed with another major dementia disease, including vascular dementia, Lewy Body disease, Huntington's disease, Creutzfeldt-Jakob disease, and Parkinson's disease.

Study Design

Enrollment

100 participants

Anticipated

Interventions and Outcome Measures

Arms

Control Group

The control group participants have not been diagnosed with mild cognitive impairment or Alzheimer's disease within the past 5 years. There are no interventions to this group.

Case Group

The case group participants have been diagnosed with mild cognitive impairment or Alzheimer's disease within the past 5 years. There are no interventions to this group.

Primary outcome measure

  • Blood Glucose Levels [ Time Frame: This will be measured throughout the study which is a period of up to 90 days. ]

Central Contacts and Locations

Central contacts

Amir Hayeri, MSc

+1-778-986-3030amir@bioconscious.tech

Locations

Bio Conscious Technologies Inc.

Recruiting

Vancouver, British Columbia, Canada, V6B 4N6

Contacts

Amir Hayeri, MSc

1-778-986-3030amir@bioconscious.tech

More Information

Sponsor

Bio Conscious Technologies Inc.

Last update posted

Nov 4, 2020

Last verified

Nov, 2020

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Bio Conscious Technologies Inc. on 2020-11-04.